Drug – bio-affecting and body treating compositions – Topical body preparation containing solid synthetic organic... – Anti-inflammatory or anti-irritant
Reexamination Certificate
2002-08-22
2008-09-02
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Topical body preparation containing solid synthetic organic...
Anti-inflammatory or anti-irritant
C424S078070, C435S007200, C435S007320, C435S028000, C514S068000, C514S100000
Reexamination Certificate
active
07419657
ABSTRACT:
The present invention relates to the identification of lipid oxidizing abzymes as a key pathogenic factor in atherosclerotic disorders. Methods and means for the reduction of abzyme mediated lipid oxidation in the vascular system are provided as therapeutic approaches for the treatment of atherosclerotic disorders. Methods are provide for determining the efficacy of treatment.
REFERENCES:
patent: 5278189 (1994-01-01), Rath et al.
patent: 6281199 (2001-08-01), Gupta
patent: 2004/0116350 (2004-06-01), Wentworth et al.
patent: 2005/0129680 (2005-06-01), Wentworth et al.
patent: 0561744 (1993-09-01), None
patent: 0669132 (1995-08-01), None
patent: WO 92/05780 (1992-04-01), None
patent: WO 97/41227 (1997-11-01), None
patent: WO 98/57622 (1998-12-01), None
patent: WO 01/22958 (2001-04-01), None
patent: WO 02/22573 (2002-03-01), None
Gupta et al. JACC. Feb. 1997, vol. 29, p. 209A, abstract 755-2.
Shoenfeld et al. Trends in Immunology. Jun. 2001, vol. 22, No. 6, pp. 293-295.
Gupta et al. Circulation. 1997, vol. 96, No. 2, pp. 404-407.
Nevinsky et al. Biochemistry. 2000, vol. 65, No. 11, pp. 1245-1255.
Wikipedia. 2006, en.wikipedia.org/wiki/Chlamydia—pneumoniae, 4 pages.
Henry, J. B. Clinical Diagnosis and Management by Laboratory Methods. 1979, vol. II, 16thEdition, W.B. Saunders Co., Philadelphia, London, Toronto, pp. 1483-1486.
Science Lab.com. www.scienclab.com/XMSDS-Picolinic—acid-9926555, May 2007.
Vertuani et al (Curr. Pharm. Design, Oct. 2004: 1677-1694).
Kalayoglu et al, Cellular Oxidation of Low-Density Lipoprotein byChlamydia pneumoniae, J Infect Disease, 1999, vol. 180, pp. 780-790.
Burian et al, Independent and Joint Effects of Antibodies to Human Heat-Shock Protein 60 andChlamydia pneumoniaeInfection in the Development of Coronary Atherosclerosis, Circulation, 2001, vol. 103, pp. 1503-1508.
Petyaev et al, Superoxide Dismutase Activity of Antibodies Purified from the Human Arteries and Atherosclerotic Lesions, Biochemical Society Transactions, Feb. 1998, vol. 26, No. 1, p. S43.
Sobal et al, Influence of Acetylsalicylic Acid on Oxidation of Native and Glycated Low-Density Lipoprotein, Life Sciences, Apr. 7, 2000, vol. 66, No. 20, pp. 1987-1998.
Steer et al, Aspirin protects low density lipoprotein from oxidative modification, Heart, 1997, vol. 77 No. 4, pp. 333-337.
Gurfinkel et al, Emerging role of antibiotics in atherosclerosis, American Heart Journal, Nov. 1999, vol. 138, No. 5, pp. S537-538.
Schwenke et al, Vitamin E. Combined With Selenium Inhibits Atherosclerosis in Hypercholesterolemic Rabbits Independently of Effects on Plasma Cholesterol Concentrations, Circ. Res., Aug. 24, 1998, vol. 83, pp. 366-377.
Fong et al, Can an Antibiotic (Macrolide) PreventChlamydia pneumoniae-Induced Atherosclerosis in a Rabbit Model? Clinical and Diagnostic Laboratory Immunology, Nov. 1999, vol. 6. No. 6, pp. 891-894.
Muhlestein et al, Infection WithChlamydia pneumoniaeAccelerates the Development of Atherosclerosis and Treatment With Azithromycin Prevents It in a Rabbit Model, Circulation, vol. 97, pp. 633-636, 1998.
Petyaev, Extraction of anti-lipoprotein abzymes from human atherosclerotic lesion: antibodies which bind and oxidise LDL, J Submicroscop Cytol Pathol; vol. 32, pp. 477 (2000).
Wentworth et al, “Antibodies have the intrinsic capacity to destroy antigens”, PNAS, Sep. 26, 2000, vol. 97, No. 20, pp. 10930-10935.
Cambridge Theranostics Ltd.
Ewoldt G. R.
Marianne DiBrino
Nixon & Vanderhye P.C.
LandOfFree
Treatment of atherosclerotic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of atherosclerotic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of atherosclerotic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3974279